Synergistic effects of progranulin and low intensity pulsed ultrasound on chondrocyte differentiation, migration and metabolism  by Uddin, S.M. et al.
Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416A144(a) closing wedge HTO (5.5 varus; range: 4.0 - 6.5; increased load; n
¼ 4), (b) opening wedge HTO (6.5 valgus; range: 2.0 - 9.5; standard
correction; n ¼ 10), (c) opening wedge HTO (11.5 valgus; range: 10.5 -
13.5; overcorrection; n¼ 5). A small stature TomoFix plate ﬁxator was
applied to stabilize the osteotomy. All left hind legs served as controls.
Animals were allowed full weight-bearing postoperatively. Six months
post operation, animals were sacriﬁced, and the cartilage defects were
evaluated by 9.4 Tesla high-ﬁeld MRI (mMR; modiﬁed 2D MOCART
score), macroscopic, micro-CT, immunohistochemical and histological
scoring as previously described. All animal experiments were con-
ducted under an Institution Animal Studies Committee approved
protocol. Data analysis was performed using SPSS Statistics (IBM,
Armonk, NY), using generalized estimating equations estimation. In
each case, an independence working correlation structure was com-
pared with a more general structure according to the Quasi-Likelihood
under Independence Model Criterion statistic. Data are given as mean
± standard deviation. P values < 0.05 were considered statistical
signiﬁcant.
Results: Macroscopic cartilage repair improved signiﬁcantly after val-
gus standard correction compared to the control (5.4 ± 3.9 vs. 8.5 ± 2.4;
1.6-fold; P ¼ 0.019), as well as color (1.2 ± 0.9 vs. 2.0 ± 0.8; 1.7-fold; P ¼
0.012), surface (1.2 ± 0.7 vs. 2.1 ± 0.8; 1.9-fold; P < 0.001) and defect ﬁll
(1.2 ± 0.8 vs. 2.0 ± 0.7; 1.7-fold; P ¼ 0.002). mMR-tomographic cartilage
repair was also signiﬁcantly better after valgus standard correction for
defect ﬁll (7.5 ± 2.4 vs. 4.2 ± 1.9; 1.8-fold; P < 0.001) and total points
(33.3 ± 15.0 vs. 22.8 ± 5.6; 1.5-fold; P ¼ 0.034). Signal intensity sig-
niﬁcantly improved for varus and valgus overcorrection (both 10.0 ± 0;
P ¼ 0.045) compared to the control group (8.2 ± 3.8) while the valgus
standard correction group performed best (11.0 ± 7.0; P > 0.05). In the
histological scoring of cartilage repair, valgus standard correction
resulted in signiﬁcant better defect ﬁll (1.7 ± 1.8 vs. 3.7 ± 0.5; 2.2-fold; P
< 0.001; Figure 1) and total points (20.3 ± 4.8 vs. 24.7± 2.9; 1.2-fold; P¼
0.011). Varus correction signiﬁcantly deteriorated cellular morphology
(4.9 ± 0.2 vs. 4.4 ± 0.7; 1.3-fold; P ¼ 0.016) and collagen type II
immunostaining (0 ± 0 vs. 1.3 ± 1.5; P < 0.001). mCT-analysis showed a
signiﬁcant decrease of bone volume density in the underlying sub-
chondral bone plate for varus (26.8 ± 19.0; 1.7-fold; P ¼ 0.046) and
valgus overcorrection (18.5 ± 22.2; 2.5-fold; P¼ 0.001) compared to the
control (45.1 ± 27.1). In the subarticular spongiosa , bone mineral
density of varus (888.9 ± 26.0; 1,1-fold; P < 0.001), valgus standard
(883.8 ± 42.4; 1.05-fold; P ¼ 0.007) and valgus overcorrection groups
(936.4 ± 47.4; 1.1-fold; P < 0.001) were signiﬁcantly increased com-
pared to the control (843.4 ± 36.5); as well as trabecular thickness for
varus (0.231 ± 0.027; 1.3-fold; P < 0.001) and valgus standard correction
(0.228 ± 0.047; 1.2-fold; P < 0.001) compared to the control (0.184 ±
0.033).
Figure 1. Histological appearance of articular cartilage repair at 6 months.
Sections are representative for the respective treatment group: a - control,
b d varus, c d valgus standard correction, d d valgus overcorrection.
Safranin O/Fast green staining, asterisks indicate integration zone, þ -
note a drill hole ﬁlled with cartilaginous repair tissue. Scale bar ¼ 1 mm.Conclusions: Valgus standard correction results in signiﬁcantly
improved cartilage repair in the medial femoral condyle compared to
the controls. Caution is warranted to avoid valgus overcorrection. These
preclinical results have important clinical implications, as they support
the concept of unloading a full-thickness cartilage defect in the weight-
bearing area of the medial femoral condyle in patients with varus
malalignment by valgisation HTO (for example in the case of failed
cartilage repair).
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SYNERGISTIC EFFECTS OF PROGRANULIN AND LOW INTENSITY
PULSED ULTRASOUND ON CHONDROCYTE DIFFERENTIATION,
MIGRATION AND METABOLISM
S.M. Uddin, B. Richbourgh, Y.-S. Yi, C. Liu. New York Univ. Med. Ctr.,
NewYork, NY, USA
Purpose: The objective of this study it to use a novel chondrogenic and
anti-inﬂammatory growth factor, progranulin (PGRN), with external
Low Intensity Pulsed Ultrasound (LIPUS) as biomechanical stimuli to i)
enhance migration, proliferation and anabolism of chondrocytes, ii)
inhibit TNFa and IL-1b induced inﬂammation and catabolism and iii)
understand the underlying mechanism for combined condroprotective
effects.
Methods: LIPUS stimulations were applied using an acoustic device,
Sonicator 740 (Mettler Electronics, Anaheim, CA) with a 10cm2 trans-
ducer (35mm diameter) with characteristic frequency of 1Mhz, pulse
duration of 200ms, with repetitive frequency of 100 Hz at an intensity of
30mW/cm2 for 20 min per day. LIPUS condroprotective effects were
analyzed by studying chondrogenesis, chondrocytes migration and
metabolism in presences of IL-1b. Furthermore, synergistic effects of
Progranulin and LIPUS were assessed by analyzing GAG content in
human cartilage explants in presence of catabolic cytokines (IL-1b and
TNFa).
Results: LIPUS induces chondrogenesis of C3H10T1/2 mesenchymal
stem cells: As shown in Fig. 1a, LIPUS signiﬁcantly enhances the
expressions of gene speciﬁc for chondrocyte differentiation, including
Sox9 and Col II in BMP-2 stimulated C3H10T1/2 Cells. Furthermore,
LIPUS stimulation was able to antagonize the inhibition of chondro-
genesis by IL-1b.
LIPUS stimulation enhances chondrocytes migration: Chondrocytes
migration was assessed through scratch assay. LIPUS stimulation
increased inﬁltration of the gap after 48 hours and nearly closed it after
72 hours. In contrast IL-1b almost completely abrogated the chon-
drocytes migration. LIPUS restored cell migration in IL-1b stimulated
chondrocytes. ImageJ analysis show signiﬁcant increase of cell inﬁl-
tration due to LIPUS stimulation and inhibited IL-1b induced cell
abrogation (Fig 1b).
Synergistic effects of PGRN and LIPUS stimulation on chondrocyte
metabolism: LIPUS increased expressions of Col II, Aggregcan and COMP
in human chondrocytes and signiﬁcantly reduced expressions of
catabolic enzymes MMP13 and ADAMTS5. Furthermore, LIPUS also
suppresses IL-1b induced expression of MMP13 and ADAMTS5.
LIPUS and PGRN together showed synergistic effects by increasing
expressions of Col II, Aggrecan and Comp by 5-6 folds (Fig 2a). Safranin
O staining of human cartilage ex-plants with most apparent GAG con-
tent in LIPUSþPGRN treated ex-plants. In contrast, IL-1b and TNF-a
showed apparent reduction in Safranin O Staining. LIPUS and PGRN
inhibited the catabolic effects of cytokines with most obvious effects in
LIPUSþPGRN treated samples (Fig 2b).
Conclusions: LIPUS alone can enhance chondrocyte differentiation in
mesenchymal stem cells and chondrocytes migration in the in vitro
assays. IL-1beta has been shown to reduce chondrocyte migration
and chondrogenesis in MSCs [1, 2], LIPUS stimulations in presence of
IL-1beta rescues chondrocytes migration and chondrogenesis. The
analysis of metabolism associated markers showed LIPUS enhances
anabolism and show chondro-protective effects against IL-1beta
induced catabolism. The combination of PGRN and LIPUS showed up
to 6 fold increase in anabolic markers and apparent increase in GAG
content of cartilage explants with apparent chondro-protective role
against IL-1beta and TNF-alpha. The combine treatment of LIPUS and
PGRN has therapeutic potential to slowing down cartilage degrada-
tion and enhancing matrix depiction in damage cartilage by
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and activating TNFR2 and Integrin associated chondro-protective
pathways (Fig 3).
Fig 1A. LIPUS enhances chondrogenesis and neutralizes IL-1beta B) LIPUS
restores IL-1beta induced chondrocytes migration inhibition.
Figure 2. A)combine treatment of PGRN and LIPUS show synergistic effects
in chondrocytes anabolism. B) LIPUS þPGRN treatment enhances saffron
O staining and protect against cytokines induce cartilage degradation.
Figure 3. PGRN and LIPUS role in inhibition of inﬂammatory and activation
of chondrogenic pathways.
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IN VITRO EVALUATION AND OPTIMIZED METHODOLOGY TO
COMBINE BONE MARROW ASPIRATE CONCENTRATE WITH BST-
CARGEL® AS A NEW INJECTABLE TREATMENT FOR CARTILAGE
REPAIR
C. Marchand y, R.L. Williams z, L.M. Grover z, M. Snow x. y Piramal
Hlth.care Ltd e Bio-Orthopedics Div., Laval, QC, Canada; zUniv. of
Birmingham, Birmingham, United Kingdom; xRoyal Orthopedic Hosp.,
Birmingham, United Kingdom
Purpose: BST-CarGel® is a chitosan-based medical device used to
treat articular cartilage defects. BST-CarGel® is mixed with thepatient’s whole blood (WB) and then injected into the cartilage
defect. BST-CarGel® /WB is intended to physically stabilize the clot,
which will guide and enhance a marrow-derived repair response.
The use of bone marrow (BM) and bone marrow aspirate concen-
trate (BMAC) (containing pluripotent mesenchymal stem cells) in
the treatment of cartilage defects has recently increased in an
attempt to perform a one-stage cell based treatment. This study
optimized the method to obtain and combine BMAC with BST-
CarGel® to create a cell seeded implant which solidiﬁes in situ and
has similar in vitro properties and advantages to the BST-CarGel®/
WB product.
Methods: Bone marrow was withdrawn from the anterior iliac crest of
4 donors using 6 X 10 mL syringes pre-loaded with 1 mL sodium
heparin (1000 Units). The 60 mL heparinized BM was ﬁltered and
concentrated as per Harvest BMAC®, SmartPrep2® system method-
ology. The BMAC cell pellet was resuspended with plasma to a ﬁnal
volume of 10 mL and analyzed for cellular composition. Upon mixture
with BST-CarGel®, the coagulation was re-activated using Plateltex®-
Act (5 Units batroxobin in 500 uL 10% calcium gluconate). BST-CarGel®/
BMAC clot properties were evaluated using an in vitro model where
0.35 mL clots were generated in glass test tubes incubated at 37C and
tested for clot retraction, clotting time and clot macroscopic appear-
ance. Chitosan distribution among clots and cellular morphology were
further characterized by histology. Cellular viability of clots placed in
chondrogenic culture media were also analyzed using 3D confocal
microscopy.
Results: The average white blood cell concentration factor obtained for
BMAC was 6.9X compared to BM. The use of sodium heparin as an
anticoagulant solution led to the BST-CarGel®/BMAC in vitro properties
being similar to BST-CarGel®/WB mixture as opposed to when ACD-A
anticoagulant was used. BST-CarGel®/BMAC clots revealed a 12.3% clot
retraction with a 5 minutes (min.) clotting time (CT) compared to BST-
CarGel®/WB clots (2.6%; 15min. CT) and WB (51.9%; 15min. CT). A
homogenous distribution of chitosan among all blood components and
normal cellular morphology were observed on histology. Cell viability
was observed within the BST-CarGel®/BMAC implant and until natural
clot degradation.
Conclusions: BST-CarGel® can be combined with BMAC, as per the
methodology described to achieve an implant with similar in vitro
properties as the current marketed product. Cell viability was observed
until natural implant degradation. This combination potentially allows
for a new single stage cell based treatment to repair challenging artic-
ular cartilage defects.
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THE INFRAPATELLAR FAT PAD FROM DISEASED JOINTS INHIBITS
CHONDROGENESIS OF MESENCHYMAL STEM CELLS
W. Wei y, R. Rudjito y, N. Fahy z, K.P. Bos y, J.A. Verhaar y, S. Clockaerts y,
Y.M. Bastiaansen-Jenniskens y, G.J. Van Osch y. y Erasmus Univ. Med. Ctr.,
Rotterdam, Netherlands; zRegenerative Med. Institue, Galway, Ireland
Purpose: The microfracture procedure is used to stimulate mesen-
chymal stem cells (MSCs) to repair cartilage defects. However, instead
of hyaline cartilage, ﬁbrocartilage is formed. This could be caused by
the inﬂuence of inﬂammatory factors in the knee. The infrapatellar fat
pad (IPFP) contains pro- and anti-inﬂammatory macrophages,
secretes many factors into the joint and its secretion pattern might be
changed by joint pathology or obesity. The goal of this study was to
investigate whether factors produced by the IPFP inﬂuence chon-
drogenesis of bone marrow-derived MSCs, whether this could be
inﬂuenced by joint pathology or obesity and whether macrophages
play a role.
Methods: IPFP obtained during total knee replacement (TKR; 22
donors), anterior cruciate ligament reconstruction (ACL; 6 donors) and
